Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)

被引：0
|
作者：
Quintas-Cardama, A.
Kantarjian, H.
Andreef, M.
Faderl, S.
Wright, J.
Zhang, W.
Konopleva, M.
Verstovsek, S.
Borthakur, G.
Cortes, J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7018
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients
    Andreeff, Michael
    Zeng, Zhihong
    Kelly, Mary A.
    Wang, Rui-yu
    McQueen, Teresa
    Duvvuri, Seshagiri
    Nowshad, Gul
    Borthakur, Gautam
    Burger, Jan A.
    Kadia, Tapan M.
    Jabbour, Elias
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Konopleva, Marina
    BLOOD, 2012, 120 (21)
  • [42] Phase II study of BAY 43-9006 using the randomized discontinuation design in patients with advanced refractory cancer.
    Ratain, MJ
    Stadler, W
    Smith, M
    Kindler, H
    O'Dwyer, P
    Flaherty, KT
    Kaye, S
    Xiong, H
    Eisen, T
    Patnaik, A
    Lee, RJ
    Lewis, J
    Schwartz, B
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6265S - 6266S
  • [43] Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
    Awada, A
    Hendlisz, A
    Gil, T
    Bartholomeus, S
    Mano, M
    de Valeriola, D
    Strumberg, D
    Brendel, E
    Haase, CG
    Schwartz, B
    Piccart, M
    BRITISH JOURNAL OF CANCER, 2005, 92 (10) : 1855 - 1861
  • [44] Final results of a phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours
    Hirte, H
    Moore, M
    Hotte, S
    Oza, A
    Siu, L
    Harris, H
    MacLean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S55 - S55
  • [45] Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
    A Awada
    A Hendlisz
    T Gil
    S Bartholomeus
    M Mano
    D de Valeriola
    D Strumberg
    E Brendel
    C G Haase
    B Schwartz
    M Piccart
    British Journal of Cancer, 2005, 92 : 1855 - 1861
  • [46] Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial.
    Welch, S.
    Hirte, H.
    Schilder, R. J.
    Elit, L.
    Townsley, C.
    Tinker, L.
    Pond, G.
    Afinec, A.
    Wright, J. J.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 276S - 276S
  • [47] Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia
    Liesveld, Jane L.
    O'Dwyer, Kristen
    Becker, Michael W.
    Mulford, Deborah
    Walker, Alison
    Chen, Rui
    Bechelli, Jeremy
    Rosell, Karen
    Jordan, Craig T.
    Minhajuddin, Mohammad
    Phillips, Gordon L., II
    BLOOD, 2012, 120 (21)
  • [48] Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis
    Holkova, Beata
    Tombes, Mary Beth
    Shrader, Ellen
    Cooke, Sheryl S.
    Wan, Wen
    Sankala, Heidi
    Kmieciak, Maciej
    Roberts, John D.
    Garcia-Manero, Guillermo
    Grant, Steven
    BLOOD, 2011, 118 (21) : 1115 - 1115
  • [49] Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia
    Plunkett, W.
    Thomas, D. A.
    O'Brien, S. M.
    Federl, S.
    Giles, F. J.
    Nicol, S. J.
    Gill, J.
    Zhao, L.
    Ravandi, F.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
    Borthakur, Gautam
    Kantarjian, Hagop
    Ravandi, Farhad
    Zhang, Weiguo
    Konopleva, Marina
    Wright, John J.
    Faderl, Stefan
    Verstovsek, Srdan
    Mathews, Sheela
    Andreeff, Michael
    Cortes, Jorge E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (01): : 62 - 68
12345